Tech Center 1600 • Art Units: 1617 1622 1623 1627
This examiner grants 31% of resolved cases
Kara Renita McMillian is a patent examiner in Tech Center 1600, working within Art Unit 1617. The examiner has 976 resolved cases and an allowance rate of 30.7 percent. This 30.7 percent rate reflects the proportion of applications that reach a grant. For the 976 cases handled, this data provides a basis for understanding the probability of success during the examination process. The volume of resolved cases reflects the examiner's experience within Tech Center 1600.
The median days to allowance for this examiner is 1340. This 1340-day timeline represents the duration for an application to move from filing to a grant. Applicants should consider this period when planning their patent strategy and resource allocation. The volume of 976 resolved cases suggests that this duration is a consistent aspect of the examiner's workflow in Art Unit 1617. This median provides a specific metric for evaluating the expected length of prosecution.
The data shows an interview lift of 37.9 percent. This 37.9 percent lift represents the change in the likelihood of allowance when an interview is conducted. It suggests that direct communication is a method for addressing the probability of a grant. For practitioners, utilizing an interview is an option to navigate the prosecution process and achieve a positive outcome. Practitioners can use this lift to evaluate the potential benefits of direct engagement.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19303084 | SOLID R-BETA-HYDROXYBUTYRIC ACID COMPOSITION | Non-Final OA | AXCESS GLOBAL SCIENCES, LLC |
| 17783220 | PARASITE CONTROL IN RUMINANTS | Final Rejection | Intervet Inc. |
| 17625425 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 17904388 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | Non-Final OA | UCL BUSINESS LTD |
| 17616248 | NOVEL SPIROBICYCLIC INTERMEDIATES | Non-Final OA | Janssen Pharmaceutica NV |
| 17530402 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | Final Rejection | Bayer Pharma Aktiengesellschaft |
| 18284897 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | Non-Final OA | Jacobio Pharmaceuticals Co., Ltd. |
| 18633164 | COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS | Non-Final OA | INXMED (NANJING) CO., LTD. |
| 18284416 | COMPOUND 7AI IN TREATING EWING SARCOMA BY INHIBITING OTUD7A | Non-Final OA | Atomwise Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy